Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia

达沙替尼 癌症研究 离体 白血病 医学 T细胞 体内 酪氨酸激酶 Jurkat细胞 药理学 伊马替尼 免疫学 受体 生物 髓系白血病 内科学 免疫系统 生物技术
作者
Jianzhong Hu,Jamie A. Jarusiewicz,Guoqing Du,Gisele Nishiguchi,Satoshi Yoshimura,John C. Panetta,Zhenhua Li,Jaeki Min,Lei Yang,Divyabharathi Chepyala,Marisa Actis,Noemi Reyes,Brandon Smart,Ching‐Hon Pui,David T. Teachey,Zoran Rankovic,Jun J. Yang
出处
期刊:Science Translational Medicine [American Association for the Advancement of Science (AAAS)]
卷期号:14 (659) 被引量:15
标识
DOI:10.1126/scitranslmed.abo5228
摘要

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy, and there is an unmet need for targeted therapies, especially for patients with relapsed disease. We have recently identified pre–T cell receptor and lymphocyte-specific protein tyrosine kinase (LCK) signaling as a common therapeutic vulnerability in T-ALL. LCK inhibitor dasatinib showed efficacy against T-ALL in preclinical studies and in patients with T-ALL; however, this is transient in most cases. Leveraging the proteolysis targeting chimera (PROTAC) approach, we developed a series of LCK degraders using dasatinib as an LCK ligand and phenyl-glutarimide as a cereblon-directing moiety. Our lead compound SJ11646 exhibited marked efficiency in cereblon-mediated LCK degradation in T-ALL cells. Relative to dasatinib, SJ11646 showed up to three orders of magnitude higher cytotoxicity in LCK-activated T-ALL cell lines and primary leukemia samples in vitro, with drastically prolonged suppression of LCK signaling. In vivo pharmacokinetic and pharmacodynamic profiling indicated a 630% increase in the duration of LCK suppression by SJ11646 over dasatinib in patient-derived xenograft models of T-ALL, which translated into its extended leukemia-free survival over dasatinib in vivo. Last, SJ11646 retained a high binding affinity to 51 human kinases, particularly ABL1, KIT, and DDR1, all of which are known drug targets in other cancers. Together, our dasatinib-based phenyl-glutarimide PROTACs are promising therapeutic agents in T-ALL and valuable tools for developing degradation-based therapeutics for other cancers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小二郎应助KYG采纳,获得30
刚刚
帆帆帆发布了新的文献求助10
刚刚
早睡早起完成签到 ,获得积分10
刚刚
Ava应助Tss采纳,获得10
1秒前
1秒前
LIULIAN应助呜啦啦采纳,获得10
2秒前
2秒前
哆啦A梦发布了新的文献求助10
2秒前
3秒前
坚定莫茗给坚定莫茗的求助进行了留言
3秒前
等你下课发布了新的文献求助10
4秒前
田様应助顺心的水之采纳,获得10
4秒前
4秒前
5秒前
momo发布了新的文献求助10
5秒前
姜姜完成签到,获得积分10
5秒前
小高子完成签到,获得积分10
5秒前
陆千万发布了新的文献求助10
6秒前
6秒前
Jasper应助xxxxx采纳,获得10
6秒前
6秒前
Lucas应助summerstar采纳,获得10
7秒前
steve发布了新的文献求助10
8秒前
Gospel发布了新的文献求助10
8秒前
哆啦A梦完成签到,获得积分10
8秒前
8秒前
9秒前
灵巧的翠桃完成签到,获得积分10
9秒前
10秒前
小蘑菇应助雪时晴采纳,获得10
10秒前
缺粥发布了新的文献求助10
11秒前
好啊发布了新的文献求助10
11秒前
11秒前
yoyo122关注了科研通微信公众号
11秒前
12秒前
摆渡人完成签到,获得积分10
13秒前
recco发布了新的文献求助10
13秒前
13秒前
竹筏过海应助二二采纳,获得30
13秒前
洪对对发布了新的文献求助10
14秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
A new approach of magnetic circular dichroism to the electronic state analysis of intact photosynthetic pigments 500
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3148815
求助须知:如何正确求助?哪些是违规求助? 2799847
关于积分的说明 7837294
捐赠科研通 2457351
什么是DOI,文献DOI怎么找? 1307824
科研通“疑难数据库(出版商)”最低求助积分说明 628276
版权声明 601663